Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.10USD
16 Feb 2018
Change (% chg)

$-0.03 (-1.18%)
Prev Close
$2.12
Open
$2.10
Day's High
$2.20
Day's Low
$2.08
Volume
51,645
Avg. Vol
79,139
52-wk High
$3.60
52-wk Low
$1.58

Latest Key Developments (Source: Significant Developments)

Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva
Tuesday, 6 Feb 2018 07:00am EST 

Feb 6 (Reuters) - Biodelivery Sciences International Inc ::BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA.BIODELIVERY SCIENCES - ENTERED INTO SETTLEMENT AGREEMENT WITH TEVA PHARMACEUTICALS USA, INC. AND TEVA PHARMACEUTICALS INDUSTRIES, LTD..BIODELIVERY SCIENCES - AGREEMENT RESOLVES BELBUCA (BUPRENORPHINE) BUCCAL FILM (CIII), PATENT LITIGATION AGAINST TEVA.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
Monday, 27 Nov 2017 07:00am EST 

Nov 27 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍BELBUCA WILL BE ADDED TO FORMULARY AS A TIER 1 LONG-ACTING OPIOID WITHOUT RESTRICTIONS​.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍CHANGES TO FORMULARY WILL GO INTO EFFECT APRIL 1, 2018​.  Full Article

BioDelivery Sciences reports Q3 loss per share $0.21
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - BioDelivery Sciences International Inc :BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.21.Q3 revenue $11.3 million versus I/B/E/S view $9.4 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

BioDelivery sciences announces patent litigation settlement agreement with Teva
Thursday, 12 Oct 2017 07:00am EDT 

Oct 12 (Reuters) - Biodelivery Sciences International Inc :BioDelivery Sciences announces patent litigation settlement agreement with Teva.BioDelivery Sciences International Inc - ‍other terms of agreement are confidential​.BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​.BioDelivery Sciences International - ‍ entered into settlement agreement with Teva Pharmaceuticals USA, Actavis Laboratories Ut, Teva Pharmaceuticals Industries.BioDelivery Sciences International Inc - ‍as part of settlement agreement BDSI has entered into a non-exclusive license agreement with Teva​.BioDelivery Sciences - settlement agreement permits Teva to first begin selling its generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier under certain circumstances.BioDelivery Sciences International - ‍ settlement agreement resolves BDSI's BUNAVAIL patent litigation against Teva pending in United States district court​.BioDelivery Sciences - ‍agreement with Teva permits Teva to first begin selling generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier​.  Full Article

BioDelivery Sciences CEO Mark Sirgo to retire
Wednesday, 23 Aug 2017 07:30am EDT 

Aug 23 (Reuters) - BioDelivery Sciences International Inc :BioDelivery Sciences president and chief executive officer Mark Sirgo to retire at year-end while continuing as vice chairman.Says CEO and president Mark Sirgo to retire.Says ‍Sirgo and board will work together during coming months to determine his successor​.  Full Article

BioDelivery Sciences reports Q2 loss per share $0.27
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - BioDelivery Sciences International Inc -:BioDelivery Sciences reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.27.Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Says ‍net revenue for Q2 ended June 30, 2017, was approximately $8.7 million compared to $29.5 million in Q1​.Q2 revenue view $8.4 million -- Thomson Reuters I/B/E/S.  Full Article

Biodelivery Sciences signs agreement with Purdue Pharma
Wednesday, 12 Jul 2017 07:30am EDT 

July 12 (Reuters) - Biodelivery Sciences International Inc :Biodelivery Sciences signs exclusive agreement with Purdue Pharma (Canada) for the licensing and distribution rights of Belbuca in Canada.‍Have signed an exclusive agreement for licensing, distribution, marketing and sale of Belbuca in Canada​.Co eligible to receive upfront, potential milestones of up to $4.5 million cad as well as royalties on sales of Belbuca​.  Full Article

Biodelivery Sciences announces Health Canada approval of Belbuca
Friday, 23 Jun 2017 07:00am EDT 

June 23 (Reuters) - Biodelivery Sciences International Inc :Biodelivery Sciences announces Health Canada approval of Belbuca®.Biodelivery Sciences International Inc says Belbuca is expected to be launched in Canada in early 2018.  Full Article

BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca, Bunavail
Wednesday, 21 Jun 2017 08:48am EDT 

June 21 (Reuters) - BioDelivery Sciences International Inc ::BioDelivery Sciences announces agreement with CVS/Caremark for Belbuca® and Bunavail® through 2020.BioDelivery Sciences International - signed agreement with CVS/Caremark extending access to Belbuca Buccal film and Bunavail Buccal film through 2020.  Full Article